TY - JOUR
T1 - Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy
T2 - Roadmap from an ELN-DAVID expert panel
AU - Ravandi, Farhad
AU - Cloos, Jacqueline
AU - Buccisano, Francesco
AU - Dillon, Richard
AU - Döhner, Konstanze
AU - Freeman, Sylvie D.
AU - Hourigan, Christopher S.
AU - Ossenkoppele, Gerrit J.
AU - Roboz, Gail J.
AU - Subklewe, Marion
AU - Thiede, Christian
AU - Arnhardt, Isabell
AU - Valk, Peter J. M.
AU - Venditti, Adriano
AU - Wei, Andrew H.
AU - Walter, Roland B.
AU - Heuser, Michael
N1 - Funding Information: This report was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA016672 and the MD Anderson Cancer Center Leukemia SPORE (Farhad Ravandi) and in part by the intramural research program of the NHLBI (Christopher S Hourigan). Publisher Copyright: © 2023 Wiley Periodicals LLC.
PY - 2023/12
Y1 - 2023/12
N2 - With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered unfit for intensive chemotherapy. While testing for measurable residual disease (MRD) is now routinely performed in patients treated with intensive chemotherapy to refine prognosis and, possibly, inform treatment decision-making, its value in the context of lower-intensity regimens is unclear. As such regimens have gained in popularity and can be associated with higher response rates, the need to better define the role of MRD assessment and the appropriate time points and assays used for this purpose has increased. This report outlines a roadmap for MRD testing in patients with AML treated with lower-intensity regimens. Experts from the European LeukemiaNet (ELN)–DAVID AML MRD working group reviewed all available data to propose a framework for MRD testing in future trials and clinical practice. A Delphi poll served to optimize consensus. Establishment of uniform standards for MRD assessments in lower-intensity regimens used in treating patients with AML is clinically relevant and important for optimizing testing and, ultimately, improving treatment outcomes of these patients.
AB - With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered unfit for intensive chemotherapy. While testing for measurable residual disease (MRD) is now routinely performed in patients treated with intensive chemotherapy to refine prognosis and, possibly, inform treatment decision-making, its value in the context of lower-intensity regimens is unclear. As such regimens have gained in popularity and can be associated with higher response rates, the need to better define the role of MRD assessment and the appropriate time points and assays used for this purpose has increased. This report outlines a roadmap for MRD testing in patients with AML treated with lower-intensity regimens. Experts from the European LeukemiaNet (ELN)–DAVID AML MRD working group reviewed all available data to propose a framework for MRD testing in future trials and clinical practice. A Delphi poll served to optimize consensus. Establishment of uniform standards for MRD assessments in lower-intensity regimens used in treating patients with AML is clinically relevant and important for optimizing testing and, ultimately, improving treatment outcomes of these patients.
UR - http://www.scopus.com/inward/record.url?scp=85169936718&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/ajh.27087
DO - https://doi.org/10.1002/ajh.27087
M3 - Article
C2 - 37671649
SN - 0361-8609
VL - 98
SP - 1847
EP - 1855
JO - American journal of hematology
JF - American journal of hematology
IS - 12
ER -